Moore Capital Management LP Acquires 95,433 Shares of Alumis Inc. $ALMS

Moore Capital Management LP lifted its stake in shares of Alumis Inc. (NASDAQ:ALMS) by 230.7% during the second quarter, Holdings Channel reports. The fund owned 136,803 shares of the company’s stock after buying an additional 95,433 shares during the quarter. Moore Capital Management LP’s holdings in Alumis were worth $3,850,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ieq Capital LLC boosted its position in shares of Alumis by 4.1% during the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after purchasing an additional 690 shares in the last quarter. Strs Ohio grew its stake in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares during the period. ProShare Advisors LLC raised its stake in Alumis by 12.4% during the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after buying an additional 1,618 shares during the period. KBC Group NV bought a new position in Alumis in the first quarter worth approximately $42,000. Finally, State of Wyoming bought a new position in Alumis in the first quarter worth approximately $57,000.

Insider Buying and Selling

In other Alumis news, insider Sanam Pangali sold 1,364 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $35,968.68. Following the sale, the insider directly owned 9,747 shares in the company, valued at $257,028.39. The trade was a 12.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jorn Drappa sold 2,447 shares of Alumis stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the completion of the sale, the insider directly owned 56,892 shares of the company’s stock, valued at approximately $1,500,242.04. This trade represents a 4.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 19,953 shares of company stock worth $534,311 in the last three months. Insiders own 33.70% of the company’s stock.

Alumis Stock Performance

ALMS opened at $21.81 on Tuesday. Alumis Inc. has a fifty-two week low of $3.76 and a fifty-two week high of $31.35. The firm has a 50-day moving average of $26.50 and a 200 day moving average of $25.05. The firm has a market cap of $2.82 billion, a P/E ratio of -5.65 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.34). The company had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. Equities research analysts predict that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. HC Wainwright restated a “neutral” rating and set a $25.00 price objective on shares of Alumis in a report on Friday, August 14th. Citigroup reaffirmed a “neutral” rating on shares of Alumis in a research note on Monday, August 17th. Wells Fargo & Company lifted their price objective on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Finally, Chardan Capital boosted their target price on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.